secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2026-04-03T23:59:59+00:00
Accession:  0001714899-26-000042
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali regains full rights to DNL593 after Takeda terminates collaboration
--------------------------------------------------------------------------

- Takeda terminated co-development agreement for DNL593 (PTV:PGRN) effective 60 days from April 3, 2026; reason is strategic, not safety/efficacy.
- Denali will continue Phase 1/2 study independently; results expected by end of 2026.
- Enrollment complete with 40 FTD-GRN participants; interim data showed dose-dependent CSF progranulin increases and favorable tolerability.
- Denali has no further financial obligations to Takeda post-termination and retains full intellectual property rights.
- DNL593 uses TransportVehicle platform, first FDA-approved BBB-crossing technology, addressing FTD-GRN with no approved slowing treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489926000042/0001714899-26-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489926000042/dnli-20260403.htm
  HTML page:      https://secwatch.observer/filing/0001714899-26-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer